This study investigates advanced solid tumors. It looks at a new investigational antibody-drug conjugate called PHN-012.
The study evaluates the safety, tolerability, and activity of the investigational medication. It also examines how the drug interacts with the body and its potential effects.
- Who can participate: Adults with advanced colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma may participate. Participants should have measurable disease and good organ function.
- Study details: Participants will receive the investigational medication.